Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28315960
DOI
10.1007/s00415-017-8461-8
PII: 10.1007/s00415-017-8461-8
Knihovny.cz E-zdroje
- Klíčová slova
- Acute ischemic stroke, Golden hour, Intravenous thrombolysis, Mobile stroke unit, Onset-to-treatment time,
- MeSH
- časové faktory MeSH
- cévní mozková příhoda etiologie MeSH
- fibrinolytika aplikace a dávkování MeSH
- intravenózní podání MeSH
- ischemie mozku komplikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- logistické modely MeSH
- následné studie MeSH
- registrace * MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- tendenční skóre MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- fibrinolytika MeSH
As there are scarce data regarding the outcomes of acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT) within 60 min from symptom onset ("golden hour"), we sought to compare outcomes between AIS patients treated within [GH(+)] and outside [GH(-)] the "golden hour" by analyzing propensity score matched data from the SITS-EAST registry. Clinical recovery (CR) at 2 and 24 h was defined as a reduction of ≥10 points on NIHSS-score or a total NIHSS-score of ≤3 at 2 and 24 h, respectively. A relative reduction in NIHSS-score of ≥40% at 2 h was considered predictive of complete recanalization (CREC). Symptomatic intracranial hemorrhage (sICH) was defined using SITS-MOST criteria. Favorable functional outcome (FFO) was defined as a mRS-score of 0-1 at 3 months. Out of 19,077 IVT-treated AIS patients, 71 GH(+) patients were matched to 6882 GH(-) patients, with no differences in baseline characteristics (p > 0.1). GH(+) had higher rates of CR at 2 (31.0 vs. 12.4%; p < 0.001) and 24 h (41 vs. 27%; p = 0.010), CREC at 2 h (39 vs. 21%; p < 0.001) and FFO (46.5 vs. 34.0%; p = 0.028) at 3 months. The rates of sICH and 3-month mortality did not differ (p > 0.2) between the two groups. GH(+) was associated with 2-h CR (OR: 5.34; 95% CI 2.53-11.03) and CREC (OR: 2.38; 95% CI 1.38-4.09), 24-h CR (OR: 1.88; 95% CI 1.08-3.26) and 3-month FFO (OR: 2.02; 95% CI 1.15-3.54) in multivariable logistic regression models adjusting for potential confounders. In conclusion, AIS treated with IVT within the GH seems to have substantially higher odds of early neurological recovery, CREC, 3-month FFO and functional improvement.
2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland
Department of Experimental and Clinical Pharmacology Medical University of Warsaw Warsaw Poland
Department of Neurology and Neurosurgery Center for Neurology Vilnius University Vilnius Lithuania
Department of Neurology and Neurosurgery University of Tartu Tartu Estonia
Department of Neurology Medical and Health Science Center University of Debrecen Debrecen Hungary
Department of Neurology Sestre Milosrdnice University Hospital Centre Zagreb Croatia
Department of Neurology University of Ioannina Ioannina Greece
Medical Faculty of Masaryk University Brno Czech Republic
Neurology Department and Stroke Center Memorial Şişli Hospital Istanbul Turkey
Neurology Department University Hospital Nitra Nitra Slovakia
Zobrazit více v PubMed
Lancet. 2004 Mar 6;363(9411):768-74 PubMed
Int J Cardiol. 2016 Jul 15;215:431-4 PubMed
Stroke. 2006 Jan;37(1):263-6 PubMed
JAMA Neurol. 2015 Feb;72(2):229-34 PubMed
Circulation. 2011 Feb 22;123(7):750-8 PubMed
JAMA. 2014 Apr 23-30;311(16):1622-31 PubMed
Circulation. 2017 Jan 10;135(2):128-139 PubMed
J Am Coll Cardiol. 2016 Jun 7;67(22):2645-55 PubMed
Neurology. 2015 Mar 24;84(12):1196-205 PubMed
Expert Rev Neurother. 2015;15(7):753-61 PubMed
JAMA Neurol. 2014 Sep;71(9):1155-61 PubMed
N Engl J Med. 2004 Nov 18;351(21):2170-8 PubMed
Neurology. 2012 Feb 7;78(6):427-32 PubMed
Stroke. 2015 May;46(5):1384-91 PubMed
Neurology. 2012 Jul 24;79(4):306-13 PubMed
J Neurol. 2015 Sep;262(9):2135-43 PubMed
Stroke. 2009 Aug;40(8):2738-42 PubMed
Stroke. 2012 Jun;43(6):1524-31 PubMed
Stroke. 2014 Sep;45(9):2555-6 PubMed
J Neurol. 2017 Jan;264(1):131-138 PubMed
JAMA. 2014 Apr 23-30;311(16):1615-7 PubMed
Lancet. 2014 Nov 29;384(9958):1929-35 PubMed
JAMA. 2013 Jun 19;309(23):2480-8 PubMed
Stroke. 2013 Oct;44(10):2808-13 PubMed
J Neurol. 2013 Feb;260(2):635-9 PubMed
Int J Stroke. 2011 Dec;6(6):493-7 PubMed
Circulation. 2007 May 22;115(20):2660-5 PubMed
Lancet Neurol. 2012 May;11(5):397-404 PubMed
Lancet. 2010 May 15;375(9727):1695-703 PubMed
Stroke. 2014 Sep;45(9):2734-8 PubMed
Neurology. 2016 Mar 22;86(12 ):1103-11 PubMed
Stroke. 2004 Jan;35(1):151-6 PubMed
Stroke. 2012 Jun;43(6):1578-83 PubMed
Stroke. 2015 Sep;46(9):2681-4 PubMed
Ann Neurol. 2012 May;71(5):634-41 PubMed
Neurology. 2009 Apr 14;72(15):1310-5 PubMed